China Oncology ›› 2022, Vol. 32 ›› Issue (10): 971-978.doi: 10.19401/j.cnki.1007-3639.2022.10.005
• Article • Previous Articles Next Articles
XU Xiaofei1(), ZHANG Lixia2, DAI Heyang3, CHEN Lingyun1, XUE Jiaojiao1, LI Qingxia1,2(
)
Received:
2022-06-23
Revised:
2022-10-13
Online:
2022-10-30
Published:
2022-11-29
Share article
CLC Number:
XU Xiaofei, ZHANG Lixia, DAI Heyang, CHEN Lingyun, XUE Jiaojiao, LI Qingxia. Value of global longitudinal strain in assessing radiation-induced heart disease in breast cancer: systematic review and meta-analysis[J]. China Oncology, 2022, 32(10): 971-978.
Tab. 1
Characteristics of included studies"
Study | Country | Mean age/year | Patient number | Number of left side n(%) | Chemotherapy n(%) | Targeted therapy n(%) | Radiotherapy dose | Cardioprotective agents n(%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
Left | Right | Left | Right | ||||||||
Erven[ | Belgium | Left: 54±13 Right: 52±11 | 30 | 20(66.7) | 12(60) | 4(40) | 4(20) | 1(10) | 50 Gy/25 f 16 Gy* | - | |
Erven[ | Belgium | Left: 54±8 Right:52±7 | 75 | 51(68) | 51(100) | 24(100) | 11(22) | 4(17) | 50 Gy/25 f 16 Gy* | - | |
Lo[ | Australia | 60.2±9.1 | 40 | 40(100) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | - | |
Tuohinen[ | Finland | Left: 63.6±6.8 Right: 62.9±4.7 | 80 | 60(75) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 42.56 Gy/16 f 16Gy* | 7(12)a 15(25)b 8(13)c | |
Yu[ | America | 52 | 47 | 26(55.3) | 26(55.3) | 43(91) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | 3(6)a 6(13)b | |||
Walker[ | France | 58±9 | 79 | 64(81.0) | 0(0) | 0(0) | 0(0) | 0(0) | 50 Gy/25 f 47 Gy/20 f 9-15 Gy* | - | |
Fourati[ | Tunisia | 50 | 103 | 60(58.3) | portion | 32(31.1) | 50 Gy/25 f 16 Gyf | ||||
Trivedi[ | Australia | 60.2±9.1 | 40 | 40(100) | 0(0) | 0(0) | 50 Gy/25 f 42.4 Gy/16 f 10 Gy/16 Gy* | - | |||
Heggemann[ | Germany | 55 | 49 | 49(100) | 20(40) | 3(6) | 61.29 Gy 52.35 Gy | - |
[1] |
LOIBL S, POORTMANS P, MORROW M, et al. Breast cancer[J]. Lancet, 2021, 397(10286): 1750-1769.
doi: 10.1016/S0140-6736(20)32381-3 pmid: 33812473 |
[2] |
TAYLOR C, CORREA C, DUANE F K, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J]. J Clin Oncol, 2017, 35(15): 1641-1649.
doi: 10.1200/JCO.2016.72.0722 pmid: 28319436 |
[3] |
GAASCH A, SCHÖNECKER S, SIMONETTO C, et al. Heart sparing radiotherapy in breast cancer: the importance of baseline cardiac risks[J]. Radiat Oncol, 2020, 15(1): 117.
doi: 10.1186/s13014-020-01520-8 pmid: 32448164 |
[4] |
ERVEN K, FLORIAN A, SLAGMOLEN P, et al. Subclinical cardiotoxicity detected by strain rate imaging up to 14 months after breast radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1172-1178.
doi: 10.1016/j.ijrobp.2012.09.022 |
[5] |
TUOHINEN S S, SKYTTÄ T, POUTANEN T, et al. Radiotherapy-induced global and regional differences in early-stage left-sided versus right-sided breast cancer patients: speckle tracking echocardiography study[J]. Int J Cardiovasc Imaging, 2017, 33(4): 463-472.
doi: 10.1007/s10554-016-1021-y pmid: 27873127 |
[6] |
SAWAYA H, SEBAG I A, PLANA J C, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients[J]. Am J Cardiol, 2011, 107(9): 1375-1380.
doi: 10.1016/j.amjcard.2011.01.006 pmid: 21371685 |
[7] |
THAVENDIRANATHAN P, POULIN F, LIM K D, et al. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review[J]. J Am Coll Cardiol, 2014, 63(25): 2751-2768.
doi: 10.1016/j.jacc.2014.01.073 |
[8] |
HEIMDAL A, STØYLEN A, TORP H, et al. Real-time strain rate imaging of the left ventricle by ultrasound[J]. J Am Soc Echocardiogr, 1998, 11(11): 1013-1019.
doi: 10.1016/S0894-7317(98)70151-8 |
[9] |
TRIVEDI S J, CHOUDHARY P, LO Q, et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer[J]. Radiother Oncol, 2019, 132: 148-154.
doi: S0167-8140(18)33547-3 pmid: 30414755 |
[10] |
FOURATI N, CHARFEDDINE S, CHAFFAI I, et al. Subclinical left ventricle impairment following breast cancer radiotherapy: is there an association between segmental doses and segmental strain dysfunction?[J]. Int J Cardiol, 2021, 345: 130-136.
doi: 10.1016/j.ijcard.2021.10.026 pmid: 34687800 |
[11] |
WALKER V, LAIREZ O, FONDARD O, et al. Early detection of subclinical left ventricular dysfunction after breast cancer radiation therapy using speckle-tracking echocardiography: association between cardiac exposure and longitudinal strain reduction (BACCARAT study)[J]. Radiat Oncol, 2019, 14(1): 204.
doi: 10.1186/s13014-019-1408-8 pmid: 31727075 |
[12] |
ERVEN K, JURCUT R, WELTENS C, et al. Acute radiation effects on cardiac function detected by strain rate imaging in breast cancer patients[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5): 1444-1451.
doi: 10.1016/j.ijrobp.2010.01.004 |
[13] |
LO Q, HEE L A, BATUMALAI V, et al. Subclinical cardiac dysfunction detected by strain imaging during breast irradiation with persistent changes 6 weeks after treatment[J]. Int J Radiat Oncol, 2015, 92(2): 268-276.
doi: 10.1016/j.ijrobp.2014.11.016 pmid: 25968824 |
[14] |
YU A F, HO A Y, BRAUNSTEIN L Z, et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy[J]. J Am Soc Echocardiogr, 2019, 32(4): 521-528.
doi: 10.1016/j.echo.2018.12.009 |
[15] |
HEGGEMANN F, GROTZ H, WELZEL G, et al. Cardiac function after multimodal breast cancer therapy assessed with functional magnetic resonance imaging and echocardiography imaging[J]. Int J Radiat Oncol Biol Phys, 2015, 93(4): 836-844.
doi: 10.1016/j.ijrobp.2015.07.2287 |
[16] |
TRAVIS L B, NG A K, ALLAN J M, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy[J]. J Natl Cancer Inst, 2012, 104(5): 357-370.
doi: 10.1093/jnci/djr533 pmid: 22312134 |
[17] |
STEWART F A, HOVING S, RUSSELL N S. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients[J]. Radiat Res, 2010, 174(6): 865-869.
doi: 10.1667/RR1862.1 pmid: 21128810 |
[18] |
SCHULTZ-HECTOR S, TROTT K R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?[J]. Int J Radiat Oncol, 2007, 67(1): 10-18.
doi: 10.1016/j.ijrobp.2006.08.071 |
[19] |
CARDINALE D, SANDRI M T, COLOMBO A, et al. Prognostic value of troponin Ⅰ in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy[J]. Circulation, 2004, 109(22): 2749-2754.
doi: 10.1161/01.CIR.0000130926.51766.CC |
[20] |
GARRONE O, CROSETTO N, LO NIGRO C, et al. Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis[J]. Cardiovasc Toxicol, 2012, 12(2): 135-142.
doi: 10.1007/s12012-011-9149-4 pmid: 22189487 |
[21] |
D’ERRICO M P, GRIMALDI L, PETRUZZELLI M F, et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer[J]. Int J Radiat Oncol, 2012, 82(2): e239-e246.
doi: 10.1016/j.ijrobp.2011.03.058 |
[22] |
STOKKE T M, HASSELBERG N E, SMEDSRUD M K, et al. Geometry as a confounder when assessing ventricular systolic function: comparison between ejection fraction and strain[J]. J Am Coll Cardiol, 2017, 70(8): 942-954.
doi: S0735-1097(17)37939-1 pmid: 28818204 |
[23] |
HO E, BROWN A, BARRETT P, et al. Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study[J]. Heart, 2010, 96(9): 701-707.
doi: 10.1136/hrt.2009.173997 pmid: 20424152 |
[24] |
HARE J L, BROWN J K, LEANO R, et al. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab[J]. Am Heart J, 2009, 158(2): 294-301.
doi: 10.1016/j.ahj.2009.05.031 pmid: 19619708 |
[1] | XU Rui, WANG Zehao, WU Jiong. Advances in the role of tumor-associated neutrophils in the development of breast cancer [J]. China Oncology, 2024, 34(9): 881-889. |
[2] | CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong. The progress of treatment for brain metastases of triple-negative breast cancer [J]. China Oncology, 2024, 34(8): 777-784. |
[3] | ZHANG Jian. Clinical consideration of two key questions in assessing menopausal status of female breast cancer patients [J]. China Oncology, 2024, 34(7): 619-627. |
[4] | JIANG Dan, SONG Guoqing, WANG Xiaodan. Study on the mechanism of mitochondrial dysfunction and CPT1A/ERK signal transduction pathway regulating malignant behavior in breast cancer [J]. China Oncology, 2024, 34(7): 650-658. |
[5] | DONG Jianqiao, LI Kunyan, LI Jing, WANG Bin, WANG Yanhong, JIA Hongyan. A study on mechanism of SIRT3 inducing endocrine drug resistance in breast cancer via deacetylating YME1L1 [J]. China Oncology, 2024, 34(6): 537-547. |
[6] | HAO Xian, HUANG Jianjun, YANG Wenxiu, LIU Jinting, ZHANG Junhong, LUO Yubei, LI Qing, WANG Dahong, GAO Yuwei, TAN Fuyun, BO Li, ZHENG Yu, WANG Rong, FENG Jianglong, LI Jing, ZHAO Chunhua, DOU Xiaowei. Establishment of primary breast cancer cell line as new model for drug screening and basic research [J]. China Oncology, 2024, 34(6): 561-570. |
[7] | Committee of Breast Cancer Society, China Anti-Cancer Association. Expert consensus on clinical applications of ovarian function suppression for Chinese women with early breast cancer (2024 edition) [J]. China Oncology, 2024, 34(3): 316-333. |
[8] | ZHANG Qi, XIU Bingqiu, WU Jiong. Progress of important clinical research of breast cancer in China in 2023 [J]. China Oncology, 2024, 34(2): 135-142. |
[9] | ZHANG Siyuan, JIANG Zefei. Important research progress in clinical practice for advanced breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 143-150. |
[10] | WANG Zhaobu, LI Xing, YU Xinmiao, JIN Feng. Important research progress in clinical practice for early breast cancer in 2023 [J]. China Oncology, 2024, 34(2): 151-160. |
[11] | LUO Yang, SUN Tao, SHAO Zhimin, CUI Jiuwei, PAN Yueyin, ZHANG Qingyuan, CHENG Ying, LI huiping, YANG Yan, YE Changsheng, YU Guohua, WANG Jingfen, LIU Yunjiang, LIU Xinlan, ZHOU Yuhong, BAI Yuju, GU Yuanting, WANG Xiaojia, XU Binghe, SONG Lihua. Efficacy, metabolic characteristics, safety and immunogenicity of AK-HER2 compared with reference trastuzumab in patients with metastatic HER2-positive breast cancer: a multicenter, randomized, double-blind phase Ⅲ equivalence trial [J]. China Oncology, 2024, 34(2): 161-175. |
[12] | CHEN Yuanxiang, YU Tao, YANG Shiyu, ZENG Tao, WEI Lan, ZHANG Yan. KDM4A promotes the migration and invasion of breast cancer cell line MDA-MB-231 by downregulating BMP9 [J]. China Oncology, 2024, 34(2): 176-184. |
[13] | HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190. |
[14] | LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200. |
[15] | CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran. A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy [J]. China Oncology, 2024, 34(11): 1036-1044. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd